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Abstract
Background: Extraskeletal Ewings sarcoma are rare tumors for which there is no consensus on
optimal management.
Methods: A retrospective review of the clinical features, treatment and outcome of patients with
extraskeletal Ewings sarcoma who reported to a single institution between January 1992 –
December 2003 is reported.
Results: A total of 19 patients with extraskeletal Ewings sarcoma were identified. Of these, 4
patients had metastatic disease at presentation and 15 patients with non-metastatic disease
received combined modality treatment with primary combination chemotherapy followed by local
treatment with radiotherapy or surgery. Disease free survival and overall survival for patients with
non metastatic disease after combined modality treatment were 60% and 30% respectively. The
significant predictors for prolonged disease free survival and overall survival were high
haemoglobin(p = 0.002), low lactate dehydrogenase (p = 0.028), chemotherapy with Vincristine,
Adriamycin, Cyclophosphamide, Ifosfamide and Etoposide regime (p = 0.008) and complete
response to chemotherapy (p = 0.001).
Conclusion:  Aggressive combination chemotherapy followed by complete surgery or
radiotherapy to a dose of more than 50 Gy is essential to confer optimal outcome for patients with
extraskeletal ewings sarcoma.
Background
Ewing's family of tumors arise primarily from bones and
rarely are of extraskeletal origin. Considering the rarity
and varied presentation of extraskeletal Ewings sarcoma
(ESES), no definite recommendation regarding optimal
treatment has been defined. The principles of manage-
ment of extraskeletal Ewings tumors have been extrapo-
lated from experience from treating Ewings sarcoma of
bony origin or primitive peripheral neurectodermal
tumors (PPNET). Commonly ESES patients are offered
combined modality treatment as for Ewing's sarcoma (ES)
of the same site and stage, though some studies have sug-
gested that extraosseous primaries may have a poorer
prognosis[1]. We are presenting a single institution expe-
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rience of management of this uncommon tumour along
with a review of relevant literature.
Patients and methods
We conducted a retrospective review of the case records of
patients who had histologically proven Ewing's family of
tumors of extraskeletal origin who reported to the Cancer
Institute between January 1992 – December 2003. Crite-
ria for inclusion in the study were a) Soft tissue tumours
without any bone involvement on CT scan, b) Histology
suggestive of Ewings family of tumors with Homer –
Wright rosettes and neurofilaments The standard patient
evaluation consisted of history and clinical examination,
complete blood counts, biochemistry, computed tomog-
raphy (CT) scan of the primary site, CT scan thorax, radi-
onuclide bone scan and bone marrow biopsy. All patients
had cytochemical studies with periodic acid shiff
stain(PAS) and immunohistochemical stains with vimen-
tin, Neuron Specific Enolase(NSE), CD 99(mic2), S100
protein to confirm neurectodermal origin and staining
with epithelial membrane antigen, cytokeratin, leucocyte
common antigen, desmin and muscle actin to rule out
other malignant tumors. Cytogenetic and electron micro-
scopic studies were conducted if samples were available.
The demographic profile, clinical characteristics, pathol-
ogy, treatment and outcome were analysed. Patient char-
acteristics which were continuous variables were
dichotomised over the median value for ease of statistical
analysis. Disease free survival and overall survival were
plotted by the Kaplan Meier method and significance of
differences between variables to predict for survival were
analysed by log rank test, with a p value < 0.05 considered
significant. Multivariate analysis of predictors of survival
were analysed by Cox proportional hazards model. Statis-
tical analysis was conducted with SPSS14 (SPSS Inc, Chi-
cago, IL)
Demographics
The study population consisted of 19 patients, 12 male
and 7 female. The median age was 21 (range 3 – 73). The
primary sites of disease were pelvis in three, retroperito-
neum in two, paraspinal region in three, extremities in
seven and thorax in four patients (table 1).
Eight patients were CD99, PAS and vimentin positive and
were categorised as Ewings sarcoma. Eight patients were
NSE and/or S100 protein positive and were categorised as
PPNET. Three patients were classified as malignant small
round cell tumour on morphology
Four patients presented with metastatic disease, one each
in the lungs, bone, bone marrow and scalp. These patients
received palliative radiotherapy and palliative chemother-
apy. All four patients had a short partial response to treat-
ment, had progressive disease soon after and a short
survival.
Treatment
The 15 patients with non metastatic disease received ini-
tial combination chemotherapy, which was scheduled to
continue for eighteen months. The three different chemo-
therapy combinations used were VAC (Vincristine, Actin-
omycin D, Cyclophosphamide), VACA (Vincristine,
Actinomycin D, Cyclophosphamide, Adriamycin) and
VAC alternating with IE (Ifosfamide and Etoposide). Five
patients each received the three chemotherapy regimes.
The median number of cycles received was 8 cycles (range
1–18)
One patient defaulted treatment and was lost to follow-
up. Of the 14 patients who completed combination
chemotherapy, 8 patients had a complete response, two
had a partial response and 4 had progressive disease.
Four of the five patients who received VAC chemotherapy,
had progressive disease while on treatment. Of the 5
patients who received VACA chemotherapy, 3 patients
had a complete response, one had progressive disease,
while one patient defaulted. All five patients who had
VAC/IE achieved a complete response and continue to be
disease free.
A total of 11 patients were assessed for local treatment.
Three patients who progressed on VAC chemotherapy and
one patient who defaulted on VACA were not available for
assessment. Of these, 8 patients had a complete response
or a very good partial response, while 3 patients had par-
tial response to chemotherapy. Three patients who had a
less than complete response underwent surgery. One
patient underwent amputation and two patients had a
complete resection of post chemotherapy residue. All
three specimens showed viable tumor with areas of necro-
sis on pathological examination.
Table 1: Patient characteristics
Total number 19
Median Age 23 years (range 3 – 73)
Male 12
Female 7
Site of disease :
Thorax 4
Upper extremity 3
Retroperitoneum 2
Paraspinal 3
Pelvis 3
Lower extremity 4
Maximum tumour diameter in cm 10.5 cm (6 – 20)
Ewings Sarcoma 8
(CD99 +, PAS+) PPNET (NSE+) 7World Journal of Surgical Oncology 2007, 5:3 http://www.wjso.com/content/5/1/3
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The patients who had a radiological complete response or
a good partial response to chemotherapy were offered
external beam radiotherapy. Six patients received 40 Gy
and three patients received more than 50 Gray.
Results
The median follow-up was 12 months. Seven patients
remain on follow-up and are disease free. Three patients
developed bone metastasis. One patient with paraspinal
tumour had a late relapse at the site of initial disease.
None of the patients who had a complete response to
chemotherapy had a late metastatic relapse. Three of the
six patients who had 40 Gy relapsed on follow-up, while
all the three patients who received more than 50 Gy
remain disease free.
The 3 year and 5 year disease free survival for all patients
were 38% and 19% respectively, and overall survival 47%
and 24% respectively. Of the 15 treated patients (exclud-
ing the patients who presented with metastatic disease),
the 3 y and 5 yr overall survival were 60 % and 30%
respectively (Figure 1 and 2).
The significant predictors of prolonged disease free sur-
vival on univariate analysis were high Haemoglobin(p =
0.002), low Lactate dehydrogenase (p = 0.028), chemo-
therapy with VAC/IE regime (p = 0.008) and complete
response to chemotherapy (p = 0.001), while male sex (p
= 0.238), site (p = 0.464), size > 10.5 cm (p = 0.7), older
age (p = 0.341), Ewings Vs PPNET (p = 0.169), low serum
alkaline phosphatase (p = 0.098), radiotherapy dose ≥ 50
Gy (p = 0.164) were not statistically significant.
The significant predictors for prolonged overall survival
on univariate analysis were similar with high haemo-
globin (p = 0.013), low lactate dehydrogenase (p =
0.022), chemotherapy regime with VAC/IE regime (p =
0.026) and complete response to chemotherapy (p =
0.001), while male sex(p = 0.482), site (p = 0.832), size >
10.5 cm (0.76), older age (p = 0.166), Ewings Vs PPNET
(p = 0.169), low serum alkaline phosphatase (p = 0.388),
radiotherapy dose ≥ 50 Gy (p = 0.065) were not statisti-
cally significant. None of the variables were found to inde-
pendently predict for disease free or overall survival on
multivariate analysis.
Discussion
Our series of nineteen patients with ESES varied in the
age, site and stage of presentation. The diagnosis of
extraskeletal ewings sarcoma requires a combination of
clinical features, radiology, pathology, immunohisto-
chemistry and molecular techniques. The following crite-
ria are proposed for the diagnosis of primary ESES: (i) no
evidence of bony involvement on magnetic resonance
imaging (ii) no evidence of increased uptake in bone or
periosteum adjacent to the tumour on static isotope bone
scan images (iii) a small round cell tumour with no differ-
entiating features on light microscopy, immunochemistry
or electron microscopy and (iv) demonstration of cyto-
plasmic glycogen[2]. Light microscopy and electron
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microscopic features of ESES and ES of skeletal origin have
been shown to be identical [3-5]. Results from previous
studies suggest that PPNET of bone or soft tissue origin are
identical and that ES (or ESES) and PPNET are histogenet-
ically related, representing different stages of cell differen-
tiation[6]. We could not detect any significant differences
in response to chemotherapy or difference in survival
between tumours which on histopathology were classified
as either Ewings sarcoma or as PPNET.
Baldini et al., have shown in his series of patients with
Ewings Sarcoma that non-skeletal primary may be an
unfavourable predictor for survival, the other adverse pre-
dictors being metastasis at diagnosis and older age[1].
Ahmad et al., in 24 patients found that younger age and
complete resection predict for a better survival in ESES [7].
Rud et al., in 42 cases noted decreased survival with pelvic
primary, incomplete resections, and presence of meta-
static disease[8].
In our series, age, site of presentation and tumour size did
not reach significance. None of the patients with meta-
static disease at presentation had a good response to
chemotherapy and all these patients had a dismal sur-
vival. Low level of haemoglobin and high lactate dehydro-
genase adversely predicted for survival, probably
reflecting initial high tumour burden.
We had used the sequence of initial systemic chemother-
apy followed by local treatment taking into consideration
the natural history of ES/PPNET where majority of failures
are distant. We found that aggressiveness of chemother-
apy was a significant factor predicting survival. Patients
with non metastatic disease were treated with primary
chemotherapy, the regime depending on the period of
presentation. Patients who presented between 1992 –
1996 received VAC regime, while those who presented
between 1996–2000 received VACA regime and those
who presented later received VAC/IE, which mirrored the
evolution of chemotherapy regimes during the study
period. Though the period of follow-up might be shorter
in patients who received VAC/IE, the results were signifi-
cantly superior to three or four drug combinations.
Patients who had a complete response to chemotherapy
had prolonged survival suggesting that initial aggressive
initial treatment may be beneficial.
The results from published studies regarding optimal
mode of local treatment has been inconsistent. Rud et al.,
and Covelli et al., have suggested that surgery has may
have a more important role in ESES than in skeletal ES
and that complete resection predicts a favourable sur-
vival[8,9]. Kinsella et al., have suggested that combined
modality therapy consisting of high-dose local irradiation
and vincristine, actinomycin D and cyclophosphamide
chemotherapy may be sufficient for ESES and that radical
surgery may be unnecessary[10]. Complete surgery if fea-
sible may be a better option considering the late side
effects of high dose radiotherapy especially second malig-
nancy. We found a dose effect for radiotherapy with a
dose of 50 Gy required for adequate control, though not
statistically significant. The role of adjuvant local radio-
therapy after complete resection is still inconclusive too
has been shown to improve increased survival[8]
From our experience all patients who received chemother-
apy with five drugs and had complete surgery or radio-
therapy to a dose of more than 50 Gy were alive with no
evidence of disease.
Conclusion
Our experience in managing extraskeletal Ewings sarcoma
underlines the importance of aggressive combined
modality treatment to confer optimal outcome for this
uncommon tumour.
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